Abstract:Background: Irritable bowel syndrome-diarrhoea (IBS-D) and IBS-mixed stool pattern (IBS-M) are disorders of gut-brain interaction characterised by abdominal pain associated with diarrhoea or both diarrhoea and constipation respectively. The pathophysiology of IBS-D/M is multifactorial and not completely understood; thus, treatment is aimed at multiple mechanisms such as altering gut microbiota, visceral hypersensitivity, intestinal permeability, gut-brain interaction and psychological strategies. Aim: The goal of this article was to provide an up-to-date review of the current evidence for both non-pharmacological and pharmacological treatment options in IBS-D and IBS-M. Future treatments for IBS-D and IBS-M will also be discussed. Methods: Medline and Embase database searches (through April 30 2021) to identify clinical studies in subjects with IBS-D in which dietary modification, alternative treatments (probiotics, acupuncture, exercise) as well as FDA-approved medications were used. Results: Dietary modification is often the first line of therapy. Furthermore, lifestyle treatments include complementary alternative medications (CAM), probiotics and peppermint oil are useful adjuncts but have not specifically been described in IBS-D/M. Evidence strongly supports psychotherapy in the treatment of IBS. Beyond over-the counter anti-diarrhoeals, anti-spasmodics and anti-depressants, pharmacological treatment now includes treating for bile acid malabsorption and the FDA-approved medications rifaximin, eluxadoline and alosetron. Conclusions: The treatment of IBS-D/M ideally involves a multidisciplinary approach of primary care, gastroenterologist and psychologist. Treatment often involves both non-pharmacological and pharmacological therapies. Future therapies may include faecal microbial transplant, Crofelemer and serotonin antagonists, but further studies are needed.

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?

New and Investigational Agents for Irritable Bowel Syndrome

New drugs in the management of the irritable bowel syndrome

Progress in the new drugs for the treatment of irritable bowel syndrome

Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

New developments in the treatment of irritable bowel syndrome

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches

Irritable bowel syndrome: recent and novel therapeutic approaches

Irritable Bowel Syndrome: A Review and Update

Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?

Current Recommendations and Evidence

Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview

Phytochemistry, ethnopharmacology and novel formulations based approaches for the treatment of irritable bowel syndrome: a comprehensive review

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

[The proven and the new in the pharmacotherapy of irritable bowel syndrome]

Antibiotics and Probiotics for Irritable Bowel Syndrome

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)

Pharmacological management of irritable bowel syndrome

Current and novel therapeutic options for irritable bowel syndrome management